Contribute Try STAT+ Today

After months of testing, the Food and Drug Administration reported finding unacceptable levels of a possible carcinogen in some metformin diabetes pills, marking the third time in two years that the same impurity was discovered in a widely used medicine.

In a brief statement, the agency noted that traces of a possible carcinogen known as NDMA were found in extended-release versions of metformin, but not in immediate-release versions. As a result, the FDA is contacting manufacturers to take “quick and appropriate action,” but did not say whether any recalls have so far occurred.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ed, could you please share the link for the FDA communication? I can see lots of reporting on this issue, but can’t find the actual FDA communication. Thanks!

    • Hi Rob

      Maybe I missed it, but I haven’t seen one. What I learned from the FDA came in the form an email sent me. If there is a communication, I will update the post, whenever one may be issued or I find it.

      ed at pharmalot

Comments are closed.